Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes
Yu Guo, Lisu Huang, Guangshun Zhang, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Structural biology of SARS-CoV-2 and implications for therapeutic development
Haitao Yang, Zihe Rao
Nature Reviews Microbiology (2021) Vol. 19, Iss. 11, pp. 685-700
Open Access | Times Cited: 399
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection
Yu‐Chyi Hwang, Ruei‐Min Lu, Shih-Chieh Su, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 194
Antibody-mediated neutralization of SARS-CoV-2
Henning Gruell, Kanika Vanshylla, Timm Weber, et al.
Immunity (2022) Vol. 55, Iss. 6, pp. 925-944
Open Access | Times Cited: 117
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
The SARS-CoV-2 neutralizing antibody response to SD1 and its evasion by BA.2.86
Daming Zhou, Piyada Supasa, Chang Liu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 14
The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
Chang Liu, Daming Zhou, Rungtiwa Nutalai, et al.
Cell Host & Microbe (2021) Vol. 30, Iss. 1, pp. 53-68.e12
Open Access | Times Cited: 63
A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
Kang Wang, Yunlong Cao, Yunjiao Zhou, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 46
Epitope profiling using computational structural modelling demonstrated on coronavirus-binding antibodies
Sarah A. Robinson, Matthew I. J. Raybould, Constantin Schneider, et al.
PLoS Computational Biology (2021) Vol. 17, Iss. 12, pp. e1009675-e1009675
Open Access | Times Cited: 40
SARS-CoV-2 Omicron spike glycoprotein receptor binding domain exhibits super-binder ability with ACE2 but not convalescent monoclonal antibody
Olaposi Idowu Omotuyi, Olujide O. Olubiyi, Oyekanmi Nash, et al.
Computers in Biology and Medicine (2022) Vol. 142, pp. 105226-105226
Open Access | Times Cited: 35
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
Development of colorimetric sensors based on gold nanoparticles for SARS-CoV-2 RdRp, E and S genes detection
Ciro Rodríguez Díaz, Nuria Lafuente-Gómez, Catarina Coutinho, et al.
Talanta (2022) Vol. 243, pp. 123393-123393
Open Access | Times Cited: 30
Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection
Yu Guo, Guangshun Zhang, Qi Yang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 15
Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview
Rukmankesh Mehra, Kasper P. Kepp
ACS Infectious Diseases (2021) Vol. 8, Iss. 1, pp. 29-58
Open Access | Times Cited: 39
Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects
Jiaqi Zhang, Shan Xing, Dan Liang, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 33
Healthcare Innovations to Address the Challenges of the COVID-19 Pandemic
Metin Akay, Shankar Subramaniam, Colin Brennan, et al.
IEEE Journal of Biomedical and Health Informatics (2022) Vol. 26, Iss. 7, pp. 3294-3302
Open Access | Times Cited: 23
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Jingjing Zhang, Han Zhang, Litao Sun
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants
Haisheng Yu, Banghui Liu, Yudi Zhang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
CCR5/CXCR3 antagonist TAK-779 prevents diffuse alveolar damage of the lung in the murine model of the acute respiratory distress syndrome
А. С. Чернов, Maksim V. Rodionov, В. А. Казаков, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Widely targeted metabolomic profiling combined with transcriptome analysis provides new insights into amino acid biosynthesis in green and red pepper fruits
Xitong Fei, Haichao Hu, Yingli Luo, et al.
Food Research International (2022) Vol. 160, pp. 111718-111718
Closed Access | Times Cited: 21
HACE2-Exosome-Based Nano-Bait for Concurrent SARS-CoV-2 Trapping and Antioxidant Therapy
Xiaoyi Ma, Shiyu Guo, Shuangrong Ruan, et al.
ACS Applied Materials & Interfaces (2022) Vol. 14, Iss. 4, pp. 4882-4891
Closed Access | Times Cited: 19
Rapid biosensing SARS-CoV-2 antibodies in vaccinated healthy donors
Sumin Bian, Min Shang, Mohamad Sawan
Biosensors and Bioelectronics (2022) Vol. 204, pp. 114054-114054
Open Access | Times Cited: 19
Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease
Bennett Davenport, Alexis Catala, Stuart Weston, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 18
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Mingtao Liu, Hui Gan, Zhiman Liang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 11
Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern
Mahali S. Morgan, Kexin Yan, Thuy T. Le, et al.
Viruses (2022) Vol. 15, Iss. 1, pp. 139-139
Open Access | Times Cited: 17
Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective
Hamideh Raeisi, Masoumeh Azimirad, Ali Nabavi-Rad, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top